Approval-standardized postmarketing safety reporting phenotypes of talquetamab versus BCMA-directed bispecific antibodies in multiple myeloma

Leukemia Research · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles